Sumatriptan Succinate Injection
Product Images NDC 43598-768

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Sumatriptan Succinate (NDC 43598-768). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr. Reddy�s Laboratories Inc.,, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Autoinjector (Autoinjector)

Label for Sumatriptan Injection USP Autoinjector System, 6 mg/0.5 mL, a single-dose autoinjector for subcutaneous injection only. The label specifies the drug form, strength, route, and that it is Rx only. It is distributed by Dr. Reddy's Laboratories Inc., made in India, with storage instructions and a barcode visible.*

FDA Label Image

Backcarton (Backcarton)

This image is an instructional diagram printed on the inside back side of a carton for Sumatriptan Succinate 6 mg subcutaneous injection by Dr. Reddy's Laboratories. The diagram includes step-by-step photographic instructions showing how to prepare and administer the injection, including removing the gray cap, pressing down the blue button, and holding the syringe at the correct angle.*

FDA Label Image

Carton (Carton)

Packaging label for Sumatriptan Injection USP Autoinjector System, 6 mg/0.5 mL strength. The carton contains 2 prefilled syringes for subcutaneous injection. It is labeled as sterile, nonpyrogenic, and Rx only, distributed by Dr. Reddy's Laboratories Inc.*

FDA Label Image

Fig (Fig)

A line graph showing the estimated percentage of subjects with relief over time (in minutes) comparing Sumatriptan and placebo. The x-axis represents time in minutes from 0 to 25, and the y-axis shows the estimated percentage of subjects with relief from 0% to 100%. Two data series are plotted: Sumatriptan (N=131) and placebo (N=127), with Sumatriptan showing consistently higher relief percentages.*

FDA Label Image

Fig1 (Fig1)

Sumatriptan Succinate Injection USP 6 mg/0.5 mL subcutaneous injection prefilled syringe by Dr. Reddy's Laboratories Inc. The image shows a clear syringe with the medication label indicating the strength and route of administration. The syringe is encased in a white plastic protective holder with a blue end cap.*

FDA Label Image

Fig10 (Fig10)

Illustration showing a hand holding a Sumatriptan Succinate 6 mg/0.5 mL subcutaneous injection device pressed against the skin. The image includes text instructing to wait 5 seconds before lifting the device after injection, indicating proper administration technique.*

FDA Label Image

Fig11 (Fig11)

An instructional illustration demonstrating the subcutaneous injection of Sumatriptan Succinate using an injection pen. The image shows a hand holding the pen inserted into the skin, with text indicating to "Take the pen off your skin" after administration.*

FDA Label Image

Fig12 (Fig12)

An illustration of a red biohazard sharps container with a white lid and an opening at the top, labeled with a WARNINGSIGN and biohazard symbol in black on an orange background. Caption reads 'Figure K'.*

FDA Label Image

Fig2 (Fig2)

An instructional diagram of a Sumatriptan Succinate 6 mg subcutaneous injection pen by Dr. Reddy's Laboratories Inc. The image labels the pen's cap, medicine window for checking clear liquid, and a blue button that must be pressed firmly to start the injection.*

FDA Label Image

Fig3 (Fig3)

An instructional illustration showing the proper sites for subcutaneous injection of Sumatriptan Succinate. The left image demonstrates injection into the thigh, and the right image shows injection into the arm, highlighting the typical locations for self-administration.*

FDA Label Image

Fig4 (Fig4)

An instructional illustration showing the Sumatriptan Succinate subcutaneous injection device before and after use. The 'Before Injection' image depicts clear liquid inside the syringe. The 'After Injection' image shows the blue plunger rod filling the window, indicating the injection is complete.*

FDA Label Image

Fig5 (Fig5)

An instructional illustration demonstrating how to remove the cap from a Sumatriptan Succinate 6 mg/0.5 mL subcutaneous injection pen by pulling the cap straight off. The diagram shows both hands holding the pen and the cap with arrows indicating the direction to pull the cap off.*

FDA Label Image

Fig6 (Fig6)

An instructional diagram showing two views of a beige plastic injection device component. The top view with a green checkmark shows the correct positioning of the internal mechanism, while the bottom view with a red X indicates the incorrect positioning. The label 'Figure E' is visible below the images.*

FDA Label Image

Fig7 (Fig7)

Instructional illustration showing a hand holding a Sumatriptan Succinate 6 mg/0.5 mL subcutaneous injection device pressed at a 90-degree angle against the skin to unlock it, with an arrow indicating downward pressure and text instructing to press down against skin to unlock.*

FDA Label Image

Fig8 (Fig8)

Illustration showing the administration of Sumatriptan Succinate injection subcutaneously. The image depicts a hand holding a prefilled syringe vertically, with instructions to press the plunger down to deliver the injection into the skin, indicated by the label 'Click' and an arrow pointing to the pressing motion.*

FDA Label Image

Fig9 (Fig9)

Instructional illustration showing the use of a Sumatriptan Succinate injection. The image depicts a hand administering the subcutaneous injection, highlighting that the blue plunger moves down to completely fill the medicine window after injection.*

FDA Label Image

Stru (Stru)

Chemical structure of sumatriptan succinate, showing the indole ring connected to a sulfonamide group and the succinate moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.